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The contribution of S2 accessory gene of equine infectious anemia virus (EIAV) to the virulence of
pathogenic strains was investigated in the present study by reverse mutation of all four consensus S2
mutation sites in an attenuated EIAV proviral strain, FDDV3-8, to the corresponding sequences of a highly
pathogenic strain DV117. The S2 reverse-mutated recombinant strain FDDVS2r1-2-3-4 replicated with
similar kinetics to FDDV3-8 in cultivated target cells. In contrast to the results of other studies of EIAV
with dysfunctional S2, reverse mutation of S2 only transiently and moderately increased the plasma viral
load of inoculated horses, and induction of transient immunosuppression did not boost viral pathogeni-
city. In addition, inoculation of FDDVS2r1-2-3-4 induced partial protection to a challenge pathogenic
virus. These results suggest that the attenuated EIAV vaccine strain with multiple mutations in multiple
genes will not easily revert to a virulent phenotype.
& 2013 Elsevier Inc. All rights reserved.Introduction
Equine infectious anemia (EIA) is an infectious disease of
equids caused by equine infectious anemia virus (EIAV), which is
a member of the Lentivirus genus of the Retroviridae family and
primarily infects and replicates in macrophages in vivo. Infected
animals are characterized by persistent infection and recurring
episodes of fever, anemia and thrombocytopenia. After approxi-
mately one year of infection, most infected horses can establish
certain levels of immunity and control over viral replication, with
subsequent progression to being a life-long inapparent EIAV
carrier. However, the replication of latent EIAV can be boosted,
which results in a relapse of EIA symptoms when host immunity is
suppressed (Leroux et al., 2004). Because EIAV-infected animals
eventually develop immunity against subsequent infection by
similar EIAV strains, EIAV and infected horses are studied as a
unique model of lentiviral infection and host immune response.
The plasma viral load is considered one of the most important
parameters for determining the pathogenicity and immunogeni-
city of viral infection (Whitney and Ruprecht, 2004). Studies havell rights reserved.shown that EIAV pathogenicity is associated with the U3 region of
the long repeat region (LTR), the surface unit of the envelope (SU,
which is also known as gp90) and the S2 accessory protein via
exchange of gene fragments between strains with different patho-
genicity or by mutation of virulence-related genes (Payne and
Fuller, 2010). Among these virulence-related genes, the S2 gene
appears to have the most obvious impact on the pathogenicity of
EIAV. The plasma viral load of the virulent EIAV strain p19/wenv17
decreased by 2.5–4.0 logs at 15–16 days post infection (dpi) and
pathogenicity was abolished after S2 expression was disabled by
deletion mutations (Fagerness et al., 2006). The Montelaro Labora-
tory created a provirus-derived attenuated EIAV strain by S2
deletion in 2003 (Li et al., 2003). This strain was applied as a live
vaccine and provided 100% protection against the challenge of a
homologous virulent strain but not against the challenge of strains
with higher variations in gp90 (Craigo et al., 2007b; Li et al., 2003).
Although EIAV strains are able to replicate in vivo to some extent
with a defective S2 gene, the lack of S2 protein may interfere with
the normal function of other viral genes or proteins. An alternative
approach to investigating the role of S2 in the virulence of EIAV is
to compare the impact of S2 proteins from strains with different
pathogenicities.
In the early 1970s, Shen et al. developed an attenuated EIAV
vaccine, EIAVDLV121 (DLV121), by ﬁrst passaging a ﬁeld-isolated
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after called LN40) and in donkeys for 117 generations (EIAVDV117,
hereinafter called DV117) to enhance the virulence and immune
immunogenicity of the virus before passaging the strain in
primary donkey monocyte-derived macrophages (dMDMs) for
120 generations to attenuate the virulence. DLV121 was used to
immunize a total of 20 million horses and mules in China from the
late 1970s to the end of the 1980s, which reduced the incidence of
EIA from 5.3% in 1978 to 0.06% in 1990 (see the document titled
“Equine infectious anemia and its control in China”, which was
issued by the Chinese Ministry of Agriculture in 1997 and written
in Chinese. The PDF version of this document is available by
request from the corresponding author and reference (Wang et al.,
2011)).
The results of experimental infection revealed that DLV121
provided protection against disease to 80% of vaccinated horses
when challenged with either LN40 (the average divergence of
gp90 from that of the vaccine was 7.1%) or the North American
strain Wyoming (the average divergence of gp90 from that of the
vaccine was 37.8%) (Lin et al., 2011; Qi et al., 2010). To evaluate the
risk of virulence reversion, plasma or homogenized spleen, liver
and bone marrow from DLV121-vaccinated horses were trans-
ferred into healthy horses. The same procedure was successively
repeated three times using plasma from inoculated horses after 14,
60 and 90 days of inoculation. No clinical EIA was observed in
these animals (see the document titled “Equine infectious anemia
and its control in China”). Experimental immune suppression was
conducted in horses inoculated with a fetal donkey dermal cell
(FDD)-adapted EIAV vaccine strain (FDDV13), and no signiﬁcant
increase in plasma viral load or EIA clinical symptoms was
observed in these horses (Ma et al., 2009). These data demonstrate
the safety and stability of these attenuated vaccines.
A comparison of the deduced amino acid sequence of S2
between pathogenic and vaccine strains of EIAV indicated that
S2 in the vaccine strains appeared to have a higher frequency of
consensus mutation. However, the open reading frame wasNucleoporin motif SH3 domain binding mot
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Fig. 1. Consensus mutation sites in the deduced S2 amino acid sequence of attenuated E
from two EIAV pathogenic strains (LN40 and DV117); four strains that were derived fro
macrophages (dMDMs) (DLV34, DLV62, DLV 92 and DLV121, respectively); and two strain
dermal (FDD) cells (FDDV13 and FDDV23, respectively). Among these in vitro-adapted s
and the other strains were fully attenuated (see the text for more details). Consensus
predicted functional motifs of S2 are also labeled. (B) Frequencies of the predominant am
were consistently mutated in most quasispecies of the avirulent strains. These reverse-unchanged (Wang et al., 2011). Combined with the existence of
multiple mutations in other genes in our EIAV vaccine strains,
these data suggest that the S2 protein may not be the primary
determinant of EIAV virulence. To further study the impact of S2
on the virulence of EIAV, the present study reverse-mutated the S2
gene in the vaccine to the sequence of a virulent strain.Results
Consensus mutations in the S2 gene of EIAV-attenuated vaccine
strains
S2 was identiﬁed as the gene with the highest frequency of
mutation in the viral genome when the genomic sequences of
several EIAV Chinese pathogenic and vaccine strains were com-
pared in a previous study by our group (Lin et al., 2011). To identify
the consensus mutation sites between the pathogenic and vaccine
S2 genes, nucleotide and deduced amino acids sequences of S2
among two highly pathogenic strains (LN40 and DV117) and two
vaccine strains (DLV121 and FDDV13) were compared. In addition,
DLV43 and DLV62 were derived from DV117 by successive passa-
ging in dMDMs for 43 and 62 generations, respectively, and were
still pathogenic. DLV92 was another daughter strain of DV117 that
was passaged in dMDM for a total of 92 generations and lost its
pathogenicity, thereby gaining the ability to induce weak immune
protection. FDDV23 was derived from the vaccine strain FDDV13
by further passaging in FDD cells for a total of 23 generations, by
which point the strain was fully attenuated but had lost the ability
to induce protective immunity against pathogenic strains. These
four additional strains were also included in the comparison of the
S2 gene sequence.
By comparing the aforementioned sequences of S2, consensus
mutations of three amino acid residues were identiﬁed among
most partial or fully attenuated strains. These mutations were the
substitutions of T41I, T51I and Q55K (Fig. 1A). An increasedif Nucleoporin localization sequence
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IAV strains. (A) Alignment of the deduced predominant amino acid sequences of S2
m DV117 for 34, 62, 92 and 121 successive passages in donkey monocyte-derived
s that were derived from DLV 121 by 13 and 23 successive passages in fetal donkey
trains, DLV34 retained the pathogenicity of DV117, DLV62 was partially attenuated
mutation sites in the avirulent strains (relative to DV117) are marked. The major
ino acid residues at one DV117-speciﬁc site (6) and three sites (41, 51 and 55) that
mutated sites are designated as r1, r2, r3 and r4, respectively.
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observed in strains of DLV62 and DLV92, which were derived
during the attenuation process (Fig. 1B). In addition, there was
another substitution of K6R in DV117 compared with LN40 after
further enhancement of pathogenicity in donkeys by successive
passaging (Fig. 1A).No signiﬁcant difference in replication in eMDMs and FDD cells
between viruses with or without a reverse-mutated S2 gene
To investigate the effect of S2 mutations on the virulence of
vaccine strains, reverse mutations of the mutated sites to corre-
sponding sequences of pathogenic strains were introduced in
the S2 gene of FDDV3-8, which is a proviral strain derived from
the EIAV vaccine strain FDDV13. Four consensus mutation sites in
the S2 of FDDV3-8 were reverse-mutated to the corresponding
sequence of DV117 as shown in Fig. 1. These reverse-mutated sites
were K6R, I41T, I51T and K55Q, and were designated as r1, r2, r3
and r4, respectively. Consequently, six molecular clones of FDDV3-8
with reverse-mutated S2 were constructed. The corresponding
viruses were derived from these proviral molecular clones and
named as FDDVS2r1, FDDVS2r4, FDDVS2r2-3, FDDVS2r1-2-3,
FDDVS2r2-3-4 and FDDVS2r1-2-3-4, correspondingly (S-Fig. 1).
The sequences of the reverse-muted sites of the S2 gene were
veriﬁed by subcloning and sequencing. In addition, expression of
the S2 protein by these viruses in FDD cells was conﬁrmed by
Western blot. The molecular weights of these mutated S2 proteins
(7.8 kDa) were identical to those of the prototype expressed by
FDDV3-8 (S-Fig. 2). Furthermore, the ability of these derived
viruses to infect and replicate in target cells was examined by
measurement of indirect immunoﬂuorescence using EIAV-positive
serum, viral reverse transcriptase (RT) activity assay (unpublished
results) and electron microscopy (S-Fig. 3).
The replication patterns of these six S2-mutated EIAV strains in
eMDMs and FDD cells were measured and compared with those of
their parental virus, FDDV3-8. The replication levels were mon-
itored by detection of viral RT activity. Except for the peak
replication of FDDVS2r1-2-3-4, which was slightly delayed relativeFig. 2. Analysis of virus replication kinetics in equine (e) MDMs. Reverse mutations w
molecular strain FDDV3-8 at different sites in different combinations. FDD cells w
chromosomal DNA. FDDVS2r1, FDDVS2r4, FDDVS2r2-3, FDDVS2r1-2-3, FDDVS2r2-3-4 a
sites r1, r4, r2+r3, r1+r2+r3, r2+r3+r4 and r1+r2+r3+r4, respectively. An equal amoun
every day to monitor viral replication status via reverse transcriptase (RT) activity as into that of FDDV3-8 in eMDMs (Fig. 2), there were no signiﬁcant
differences in replication between the six recombinant EIAV
strains and the FDDV3-8 control at each of the examined time
points in FDD cells (S-Fig. 4).Inoculation of FDDVS2r1-2-3-4 did not result in typical clinical EIA
To detect the effect of reverse-mutated S2 on the pathogenicity
of vaccine strains, four EIA naive horses were inoculated with
FDDVS2r1-2-3-4 (#3, #4, #8 and #35, Group A), and EIA clinical
signs and plasma viral loads were observed for 6 months. These
horses were compared with horses inoculated with the parental
strain FDDV3-8 (#15, #28, #31 and #34, Group B).
Plasma viral load is considered the most important single
indicator for evaluating the pathogenicity of EIAV. The dynamic
changes in the average plasma viral loads in the horses of both
Group A and Group B over a period of 167 days are presented in
Fig. 3A. The dotted line indicates the threshold of the plasma viral
load for the vaccine strain, which was based on the average viral
load of FDDV3-8 in four horses of Group B with a duplicated
standard deviation. Viral loads in Group B horses were under the
line at all time points, whereas the viral loads in Group A were
above the threshold at the four time points, with the peak load
occurring around 40 dpi. However, all viral loads in the horses of
Group A were lower than 1107 copies/ml, which is one of the
diagnostic criteria for clinical EIA (shown as a solid line in Fig. 3A).
Because the difference in viral load between Groups A and B was
observed only within approximately three months after inocula-
tion, the viral loads of these groups at 100 dpi were statistically
analyzed. The mean values of the viral copies of Group A and
Group B were 4.82104/ml and 1.67105/ml, respectively, and
P¼0.0074, which indicated a signiﬁcant difference (Fig. 3B).
Body temperature (439 1C) and platelet counts (o100,000/μl)
are also criteria for diagnosing clinical EIA. There were no
abnormal body temperature values or platelet counts in either
group of horses. Combined with the plasma viral load data, these
ﬁndings suggest that acute EIA was not induced by inoculation of
FDDVS2r1-2-3-4. However, further analysis revealed that theere induced in the S2 gene of the proviral chromosomal DNA of the attenuated
ere transfected with recombinant plasmids containing corresponding proviral
nd FDDVS2r1-2-3-4 are derived viruses containing S2 with reverse mutations at
t of virus (1000 PFU) was inoculated into the eMDMs. The samples were collected
dicated by optical density (OD405).
Fig. 3. Comparison of plasma viral loads in groups of horses inoculated with
FDDVS2r1-2-3-4 and FDDV3-8. (A) Dynamic change of plasma viral loads. Four
horses in each group were subcutaneously inoculated with 2 ml of 1105 plaque-
forming units (PFU)/ml of either FDDVS2r1-2-3-4 or FDDV3-8. The immuno-
suppressant dexamethasone was injected 167 days after inoculation for 14
continuous days at 0.11 mg/kg body weight to transiently induce immunosuppres-
sion (shaded area in the ﬁgure). Real-time PCR was used to detect plasma viral
loads at different days post infection (dpi). The broken line represents two SDs over
the mean viral load of attenuated FDDV3-8. The solid line represents the threshold
of the plasma viral load for clinical EIA (1107 copies/ml).↓ indicates the time of
challenge with the pathogenic strain LN40. (B) Statistical analysis of the difference
in plasma viral load between the groups of horses within 100 dpi of FDDVS2r1-2-3-
4 and FDDV3-8 administration.
Table 1
Primers used in this study.
Primer Sequence(50–30)
Location in viral
genome of FDDV3-8
S2up ACAAAGGGAGGGAAAGTATG 4861–4890 nt
S2down TCGCGAaTGCATGTCTGTGAT 7327–7356 nt
P7 CCACCAGAGTGTTGTGGAAAGGTGA 5017–5046 nt
P8 TGACCCCATGATTCATTCCA 6975–7004 nt
m17up GGATTATTTGGTAGbAGGGGTAACATGGTCA 5296–5325 nt
m17down TGACCATGTTACCCCTCTACCAAATAATCC 5296–5325 nt
m122up ACAGAAAGGGGATCACATGGTATATCAACC 5399–5428 nt
m122down GGTTGATATACCATGTGATCCCCTTTCTGT 5399–5428 nt
m152up CTATTGTTATAATGCCAGCCATAAAGCAGA 5429–5458 nt
m152down TCTGCTTTATGGCTGTCATTATAACAATAG 5429–5458 nt
a Restriction site for NruI.
b Reverse-mutated sites.
Table 2
Coefﬁcient tests for viral load, body temperature and platelet count in horses
inoculated with either FDDVS2r1-2-3-4 or FDDV3-8.
FDD3-8 FDS2r1-2-3-4
Temp. vs Platelet 0.8935n 0.0025
Temp. vs Viral load 0.7278 o0.0001
Viral load vs Platelet 0.9376 0.0004
n P values indicate signiﬁcant differences.
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signiﬁcantly correlated in the horses of Group A (Po0.01), i.e.,
increased plasma viral load was correlated with increased body
temperature and decreased platelet count (Table 2). The changes
of these three virological and clinical values in the control horses
of Group B appeared to have no correlation (P40.05).
To determine the stability of the reverse mutations in the S2
gene of FDDVS2r1-2-3-4 in vivo, the S2 gene fragments of horsesin Group A and Group B were cloned at 23, 65 and 200 dpi, and ten
clones for each horse at each time point were sequenced. There
were no identiﬁed mutations at these reverse-mutated sites. In
addition, Western blots indicated that S2 protein was expressed in
the PBMCs of all horses infected with either FDDVS2r1-3-4-5 or
FDDV3-8 at 65 dpi (unpublished results).
These results indicate that the reverse mutation of S2 in a
vaccine strain to the S2 sequence of a virulent strain did not
change the virus into a pathogenic strain, although the virulence
was temporally and moderately increased, particularly in the
middle phase of infection.
Transient immunosuppression increased the plasma viral loads of
horses infected with FDDVS2r1-2-3-4 and FDDV3-8 but did not
induce clinical EIA
Plasma viral load is considered the most important single
indicator for evaluating the pathogenicity of EIAV and is largely
controlled by the host immunity. Studies have demonstrated
that transient immunosuppression (TIS) induced by the treat-
ment of dexamethasone could dramatically increase plasma
viral loads of vaccine and challenge virus in vaccinated horses
resulting in 6 of the 12 inoculated horses exhibited clinical signs
of EIA (Craigo et al., 2007a) and the infected pathogenic virus in
an asymptomatic carrier positive control horse (Ma et al., 2009).
Therefore, TIS is a rigorous approach to evaluate the protective
efﬁcacy of vaccines and potential virulence of attenuated
viruses. This approach was applied to further examine the
potential virulence of FDDVS2r1-2-3-4. TIS was induced in
horses of Groups A and B by daily injection of dexamethasone
for 14 days from 167 dpi. Immunity was shown to be signiﬁ-
cantly suppressed when examined at the 10th day of injection
for delayed-type hypersensitivity (DTH) and lymphocyte pro-
liferation (S-Fig. 3).
Compared with 102–104-fold higher plasma viral loads of
vaccine or challenge viruses and the appearance of clinical signs
of EIA in immunosuppressed horses as reported by Craigo et al.
and the 103-fold increase in the virus in the positive control horse
reported by Ma et al., although the plasma viral loads of horses
infected with FDDV3-8 (Group B) were increased 10- to 100-fold,
the virus level in horses infected with FDDVS2r1-2-3-4 (Group A)
was basically unchanged during and immediately (approximately
a month) after immunosuppression. Importantly, the viral copy
numbers in the horses of both the groups were lower than
1107 copies/ml, which is the threshold of clinical EIA (Fig. 3A
and Fig. 4). In addition, no horses in Group A presented fever
(439 1C) or thrombocytopenia (o100,000 counts/ml), which are
the other two signs of clinical EIA. In contrast, in Group B, horse
#15 had short episodes of fever on day 7 (39.8 1C) and day 15
(40.3 1C) after the TIS treatment. Horse #28 also presented a
slightly increased temperature on day 6 (0.2 1C over the normal
temperature of 39 1C). The remaining horses (#31 and #34) had
normal body temperatures. The platelet counts of all four horses in
this group were within the normal range (Fig. 4), which suggests
that horses #15 and #28 had atypical EIA or merely a side effect.
Horse #28 died 55 days after TIS. Based on the plasma viral load,
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Fig. 4. Changes in body temperature, platelet count and viral load in horses infected with FDDVS2r1-2-3-4 (Group A) or FDDV3-8 (Group B). Four EIA-naïve horses in each
group were inoculated with 2 ml of 1105/ml PFU of either virus. An additional four horses were mock-inoculated with PBS as healthy controls (Group C). Body temperature
was measured twice daily. An automatic blood analyzer was used to measure the platelet counts. Real-time PCR was used to determine plasma viral loads. Transient
immunosuppression (TIS) was induced in horses of Group A and Group B at 167 dpi by injection of dexamethasone for 14 continuous days (shaded area in the ﬁgure). The
horses of these two groups and two healthy control horses (Group D) were challenged by subcutaneous infection of 1104 TCID50 with a pathogenic strain LN40 at 259 dpi
(indicated by ↓).
X. Gao et al. / Virology 443 (2013) 321–328 325body temperature and platelet counts within two weeks before
death, as well as the pathologic anatomy results, this animal died
of reasons other than EIA.
Consequently, these results implicate that the virological fea-
ture of FDDVS2r1-2-3-4, but not the host immunity, predomi-
nantly controlled the replication of this virus in the host and
mutations in the S2 gene alone in this virus does not signiﬁcantly
change this feature.
Inoculation of FDDVS2r1-2-3-4 or FDDV3-8 only elicited partial
protection against clinical EIA generated by challenge virus
To further examine the immune protection induced in horses
inoculated with FDDVS2r1-2-3-4 and FDDV3-8, animals in these
two groups and the positive controls for the challenge virus
(Group D) were challenged by subcutaneous infection of 1104
TCID50, of the pathogenic strain LN40 at 78 days after the end of
TIS. DTH and lymphocyte proliferation levels returned to the levels
in healthy control animals observed 2 days before the infection of
the challenge virus (76 days after the end of TIS).
Typical EIA was observed in two horses of Group D (# 37 and
#38) at 20 days after challenge. These two horses were euthanized
four days later when they began demonstrating severe disease-
associated symptoms resulting in distress (Fig. 4). Among thehorses inoculated with FDDVS2r1-2-3-4 (Group A), horses #3 and
#8 presented typical EIA symptoms at 40 days after the challenge.
All clinical signs (plasma viral load, body temperature and platelet
counts) returned to normal levels in approximately a week, and
these normal levels lasted to the end of the experiment (120 days
post-challenge). The other two horses of this group (#4 and #35)
did not present detectable EIA signs until the end of the experi-
ment. Of the horses inoculated with FDDV3-8, one horse (#15)
died because of declining body condition with no signs of EIA 34
days after the end of TIS. Among the remaining three horses, #15
was euthanized 15 days after challenge because of severe EIA, and
#31 presented a typical EIA episode at 25 days post-challenge but
returned to normal a week later and survived to the end of the
experiment. Horse #34 did not present any EIA signs throughout
the experimental period (Fig. 4).
Discussion
Our previous experiments for inducing transient immunosup-
pression in horses vaccinated with attenuated Chinese EIAV
vaccines revealed that this treatment did not signiﬁcantly enhance
the plasma viral load or trigger EIA clinical signs (Jiang et al., 2011;
Ma et al., 2009) and data of this study). These results suggest that
the under-pathogenic threshold-replication of these vaccine
X. Gao et al. / Virology 443 (2013) 321–328326strains was not caused by the suppression of host immunity but
rather was based on the changes of the biological features of these
viral strains.
S2 is similar to the Vpu accessory protein of HIV-1 with regard
to genomic position and some similar protein functional motifs,
such as a domain that permits binding to the cell membrane, SH3-
binding motifs and a pair of serine residues that are constitutively
phosphorylated by casein kinase II, as discussed by Fagerness et al.
(2006) and Covaleda et al. (2010). However, functionally, S2 is
more similar to the Nef protein of HIV-1 and SIV. Nef is considered
to directly enhance virion productivity and viral infectivity. Similar
to S2-defective EIAV, although Nef deﬁciency had no detectable
effect on SIV replication in cultured cells, such strains demon-
strated dramatically impaired viral replication in infected hosts
and could be retained in hosts for several years without inducing
pathologic signs (Kestler et al., 1991). Both the S2-defective EIAV
and Nef-defective SIV were tested as attenuated live vaccines and
induced protection against challenges from several pathogenic
strains (Craigo et al., 2007b; Daniel et al., 1992; Li et al., 2003;
Wyand et al., 1999).
In contrast to previous studies reported by Fagerness et al. (2006)
and Li et al. (2003), in which defective S2 signiﬁcantly retarded
in vivo replication and disabled the pathogenicity of virulent strains,
the reverse mutation of the S2 gene sequence of an attenuated EIAV
strain to that of its parental pathogenic strain in the present study
did not reverse the pathogenicity of the attenuated virus, although
this approach transiently and moderately increased the amount of
plasma RNA copies of this virus. These results suggest that although
functional S2 protein is important for EIAV replication in vivo, it is not
the only factor determining the pathogenicity or virulence of EIAV
with an intact and functional genome.
In previous studies, we compared the genomes of several
EIAV Chinese pathogenic and attenuated strains and observed
that multiple mutations appeared in all of the genes of these
attenuated viruses, especially in the LTR, env and three acces-
sory genes,
i.e., tat, S2 and rev (Wang et al., 2011). These frequently mutated
genes are similar to the virulence-associated genes of EIAV
suggested by other studies (Payne and Fuller, 2010). It is
presumed that the combined effect of these multiple mutations
in multiple genes enable the attenuated viruses to adapt to the
environment of in vitro cultivated cells and consequently stably
suppress the in vivo replication of these viruses under the
pathogenesis threshold. The reverse mutation of some of the
virulence-associated sites did not sufﬁciently reverse the
attenuation of pathogenicity. In addition, the appearance of
certain pathogenesis-related amino acid residues in the gp90
surface protein identiﬁed in our previous studies (Ma et al.,
2009) could increase the antigenicity of the virus. These viruses
have lost pathogenicity, which enables hosts to develop proper
immunity against subsequent infection of pathogenic strains if
the antigens provided by the live attenuated viral strains can
induce immunity that is broad and strong enough to block the
immune evasion of the pathogenic strains.
Unpublished historic experiments performed in this laboratory
in the early 1970s demonstrated that although the DLV62 virus
still caused disease on horses at the similar rate (near 100%), the
mortality was reduced by about half and the clinical signs were
not as severe as caused by the parental viruses DV117 and DLV34.
More evidently, the modality on donkeys was noticeably dropped
from 100% caused by DV117 and 67% caused by DLV34 to 50%
when infected with the DLV62 virus. In addition, even though the
S2 in DLV62 is more similar to that of attenuated viruses, there
were still some clones contained sites that were speciﬁc for
pathogenic strains (such as r2 and r3, see Fig. 1B). Furthermore,
the effect of other genes required for expression of virulence inDLV62 might also contribute to the pathogenicity of this virus
(Payne and Fuller, 2010; Wang et al., 2011).
In conclusion, this study indicates that reverse mutation of the
virulence-associated S2 gene in the attenuated EIAV strain to the
sequence of virulent strains does not sufﬁcient to cause the virus
to revert to pathogenicity. In addition, our data also suggest that
the existence of multiple mutations in multiple genes is the major
reason for the stable reduction of virulence in Chinese attenuated
EIAV vaccine strains.Materials and methods
Animal, cells and viral strains
All horses used in the experiments were EIAV antibody-
negative, as determined by two separate agar gel immunodiffusion
assay tests. The horses and related experimental protocols used in
this study were approved by the Institutional Animal Care and Use
Committee (IACUC) of the Harbin Veterinary Research Institute
(HVRI) at the Chinese Academy of Agricultural Sciences. All of the
animals were cared for according to the institutional guidelines.
Some horses that were infected with EIAV pathogenic strains were
euthanized at the end of experiment or when they presented
severe disease-associated symptoms resulting in distress. The
horses were euthanized via intravenous injection of pelltobarbi-
talum natricum (100 mg/kg of body weight, dissolved in saline) in
the jugular vein by veterinarians according to protocols approved
by the IACUC of the HVRI.
Fetal donkey dermal (FDD) cells were proliferated from the
stock of the Cell Bank of Epidemic Disease Examination and
Service Center of the HVRI. Equine monocyte-derived macro-
phages (eMDMs) were prepared from peripheral blood mono-
nuclear cells (PBMCs) that were isolated from 200 to 300 ml of
horse peripheral blood taken from the jugular vein by veterinar-
ians as described previously (Jiang et al., 2011).
The EIAV virulent strains LN40 and DV117, the donkey MDM-
adapted live vaccine strain DLV121, and FDDV3-8, which is a
proviral derivative of the FDD cell-adapted vaccine strain FDDV13,
were described previously (Wang et al., 2011).
Analysis of the EIAV S2 gene sequence
Viral RNA was extracted from the plasma of EIAV-infected horses
or the culture medium of EIAV-infected cells using the QIAamp Viral
RNA Mini Kit (Qiagen, MD, USA) and was reverse transcribed into
cDNA using the EIAV-speciﬁc primer p8 (Table 1) and an M-MLV
reverse transcriptase system (Invitrogen, USA) following the manu-
facturers' protocols. The S2 fragment was ampliﬁed from EIAV cDNA
by reverse transcription (RT)-PCR using the primers p7 and p8. The
PCR reaction mixture included 1.25 U of DNA polymerase, 0.5 mmol
of dNTP, 1.2 mmol of MgCl2, 10 μmol of each primer and 1.25 ng of
cDNA in a 25-μl reaction volume. Ampliﬁcations were performed
with 35 cycles at 94 1C for 45 s, 53.6 1C for 30 s and 72 1C for 2 min.
The ampliﬁed products were ligated into the pMD18-T vector
(TaKaRa, Japan) after gel extraction and transformed into E. coli
DH-5a competent cells. Twelve clones from each sample were
randomly selected and analyzed for the sequence of the insert.
Pairwise and multiple sequence alignment were conducted using
the DNAstar software package (DNAStar, USA).
Reverse mutation of vaccine S2 to the S2 sequence of pathogenic
strains
A 2486 bp fragment between the NcoI and NruI sites was ﬁrst
ampliﬁed from pFDD3-8, a plasmid containing the proviral
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using primers S2up and S2down (Table 1) and was then subcloned
into the pMD18-T vector. Four reverse-mutated sites were intro-
duced into the subcloned S2 gene in different combinations by one
to three PCR reactions using the set of three up and down primer
pairs (m7, m122 and m152) listed in Table 1. Consequently, six
recombinant plasmids were constructed, which contained the
2486 bp EIAV genomic NcoI/NruI fragment with one to four sites
in the S2 gene revers-mutated. After examined by full length
sequencing, these engineered NcoI/NruI fragments were subcloned
into pFDD3-8 to substitute the original corresponding fragment of
the proviral clone of the attenuated EIAV strain. The engineered
NcoI/NruI fragments in ﬁve of the six recombinant proviral clones
were re-sequenced. In addition, the full genomic sequence of the
proviral clone pMD18-T-S2r1-2-3-4, which was used to derivate
the recombinant proviral strain FDDVS2r1-2-3-4 for in vivo stu-
dies, was determined.
Proviral derivatives of EIAV vaccine strain with reverse-mutated S2
The S2 gene of FDDV3-8 was substituted with the S2 fragment-
containing gene with two, three or four reverse-mutated sites.
Recombinant plasmids that carried the reverse-mutated EIAV
genomes were transfected into FDD cells using the transfection
regent Lipofectamine 2000 (Invitrogen). Recombinant viruses
were harvested from transfected cells after two freeze-and-thaw
cycles at 10–12 days post-transfection, when an obvious cyto-
pathic effect (CPE) was observed.
Virus titers were quantiﬁed using a Reverse Transcriptase Assay
Colorimetric Kit (Roche, IN, USA) and then used to infect FDD cells
that were plated in 6-well plates. The infected cells were ﬁxed
with 3.7% formaldehyde and assayed with 1:100 diluted EIAV-
positive horse serum; binding was visualized by reaction with
1:5000 diluted FITC-labeled rabbit anti-horse IgG (Sigma, USA)
and observation under ﬂuorescence microscopy. Reverse-mutated
sites in the recombinant EIAV were veriﬁed by sequencing of the
S2 gene after the fragment was ampliﬁed by RT-PCR and sub-
cloned into the pMD18-T vector.
Detection of replication efﬁcacy of reverse-mutated EIAV in cultivated
cells
Reverse-mutated EIAV produced by transfected FDD cells was
collected and then successively passaged in FDD cells for three
generations. The viruses were collected 14 days after the third
passage from infected cells by two freeze-and-thaw cycles. The
viral RT activity in the supernatant of the cell lysate was examined,
and the minimal infectious dose (MID) of the viral preparations
was measured with dilution to reach a 10-fold RT value relative to
the negative control. Viral solution that contained 100 MID (1 ml)
was added to each ﬂask (25 cm2) of FDD or eMDM cells (approx-
imate 5106 cells) and incubated at 37 1C for 1 h. After three
washes using serum-free MEM culture medium, the cells were
further cultivated in 6 ml of fresh full medium. A portion of culture
medium (200 μl) was sampled daily and stocked at −80 1C until the
viral RT activity assay. The sampling lasted for 7 days for infected
eMDMs or 18 days for infected FDD cells. The replication features
of viruses were analyzed by graphing the RT activity versus the
time. The titers of EIAV in FDD cells were also measured using a
plaque-forming assay as previously described (Jiang et al., 2011).
EIAV infection of experimental horses
In total, 12 EIAV-negative healthy horses were used and
randomly divided into four groups in this study. Group A consisted
of four horses (#3, #4, #8 and #35) that were subcutaneouslyinoculated with 2 ml of 1105 plaque-forming units (PFU)/ml of
the recombinant virus S2r1-2-3-4, a derivative of FDDV3-8, in
which all four mutation sites (sites 1, 2, 3 and 4; see Fig. 1) in the
S2 were reverse-mutated. Group B contained four horses (#15,
#28, #31 and #34) that were inoculated with the same dose of
FDDV3-8 as previously described (Jiang et al., 2011). In addition,
four horses were inoculated with 2 ml of PBS as healthy controls
(Group C). To evaluate the immunity induced by attenuated
FDDV3-8 and S2r1-2-3-4, the horses inoculated with these viruses
were challenged with a pathogenic strain, LN40, by subcutaneous
injection of 1104 TCID50 (50% of the tissue culture infective dose)
of this virus, at 259 dpi. In addition, two mock-inoculated horses in
the Group C were challenged with LN40 on the same day as
Groups A and B as controls for the challenge virus (Group D).
The body temperature of the horses was monitored twice a day,
and peripheral blood was taken from the jugular vein at indicated
time points for clinical, immunological and virological analyses.
The hemocyte and platelet counts were measured using an MS4-5
hematology analyzer (Melet Schloesing Laboratories, France). The
plasma layer was ultracentrifuged at 100,000g for 1 h, and viral
RNA in the precipitate was extracted using a QIAamp Viral RNA
Mini Kit (Qiagen). The viral load in the plasma was analyzed using
a previously described method (Jiang et al., 2011; Lin et al., 2011).
The S2 nucleotide sequence of the infected viruses was examined
at the 23, 65 and 200 dpi.Transient immunosuppression (TIS) of EIAV-infected horses
The immunity of EIAV-infected horses (groups A and B) was
transiently suppressed by injectionwith dexamethasone (0.11 mg/kg)
daily for 14 days from 167 dpi as described previously (Ma et al.,
2009). Delayed-type hypersensitivity (DTH) and lymphocyte prolif-
eration were measured for evaluating the effect of immune suppres-
sion after 10 days of drug treatment. The physical signs (body
temperature and platelets) and changes of plasma viral load in the
horses were monitored as well. The DTH and lymphocyte prolifera-
tion levels were measured again 2 days before infection by the
challenge virus (76 days after the end of TIS).Western blot of S2 protein in the reverse-mutated EIAV strain
Lysates of FDD cells infected with the reverse-mutated EIAV
strain S2r1-2-3-4 were prepared by homogenizing the cells with
100 ml RIPA buffer/well. Viruses in infected plasma were collected
by ultracentrifugation at 100,000g for 1 h and suspended in the
proper volume of RIPA buffer. After measurement of protein
concentration to conﬁrm equal loading, the viral proteins were
separated by SDS-PAGE and transferred to a PVDF membrane for
detection with rabbit anti-S2 antiserum prepared in this labora-
tory. The proteins that reacted with the S2 antiserum were then
incubated with an HRS-labeled anti-rabbit mouse IgG (Sigma) and
visualized by reaction with ECL Plus Western Blotting Detection
Reagents (Amersham, USA).Acknowledgments
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